From Dana Lyons: Last fall, we laid out the foundation for the current rally in pharmaceutical and biotech stocks; we take stock of those setups and the sectors’ present prospects. NASDAQ:IBB June 29, 2017 8:55am

It has been some time since we last spoke about the Biotech Equity segment in this piece, as the sector was simply not a solid performer through much of 2016 and has only recently come to life here in mid-2017. NASDAQ:IBB June 26, 2017 11:50am

From Franklin Templeton Investments: Changing political policies and priorities can impact certain market sectors—for better or worse. Health care costs and prescription drug pricing were hot-button issues in the United States during the 2016 presidential election, and the Trump administration has been pushing forward its own health care agenda. NASDAQ:IBB June 7, 2017 5:57am

The CEOs of several prominent biotech companies joined forces with the head of the National Institutes of Health (NIH) today in Washington to try and convince the White House not to seek major budget reductions for medical research. NASDAQ:IBB May 8, 2017 4:17pm

From Taki Tsaklanos: Stock market indexes gain around 1 percent on Thursday. The small cap index Russell 2000 rose around of 1.15%, making it the best performing U.S. stock market index of the day. NASDAQ:IBB April 21, 2017 6:21am

From David Fabian: I’m normally an optimistic, “glass-half-full” kind of guy. I roll my eyes every time I see a headline decrying the next market crash or cataclysmic event that will cripple the global economy. I’m quick to discern speculation from truths and prefer taking the opposite side of most mainstream assumptions. NASDAQ:IBB March 23, 2017 6:26am

From Zacks: 2016 was a tough year for biotech stocks with the sector facing a lot of criticism for rising drug prices. Although shares did rally post-election in November on hopes that drug pricing would not be a key focus area under a Donald Trump presidency, the rally turned out to be short-lived following the President’s views regarding drug pricing. NASDAQ:IBB March 14, 2017 7:54am

From Taki Tsaklanos: Biotechnology stocks are breaking out. They have been consolidating for nearly 20 months. Investors lost interest...and that is exactly what smart investors, in general, want to see in order to buy a market. NASDAQ:IBB March 3, 2017 6:13am

The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue. NASDAQ:IBB February 20, 2017 6:42am

From Taki Tsaklanos: Biotechnology was once the darling of stock market investors. Not so anymore, since the summer of 2015 the sector collapsed from 400 points to 250 points in the IBB ETF. NASDAQ:IBB February 17, 2017 6:33am

From Jon Markman: It really is a brave new world. Not long ago, a group of prominent scientists announced plans for a project to create synthetic human DNA from scratch. NASDAQ:IBB February 14, 2017 9:21am